|
WKN 883396 hier eine aktuelle Meldung. Ich habe mich schon gewundert warum der Kurs gestiegen ist. Habt Ihr Meinungen oder andere Infos ??Canadian Company Press Release IBT 2000-03-01 (provided courtesy of Canadian Corporate News.) register to receive future releases by email from CCN Recent Studies Suggest IBEX Drug Neutralase(TM) Effective on New Class of Anticoagulants MONTREAL, QUEBEC--Recent studies demonstrate that Neutralase is the most effective agent in reversing the new class of anticoagulants which are now coming to market for a wide range of clinical uses. These experiments were conducted in the laboratories of Professor Jawed Fareed and colleagues at Loyola University Medical Center (Chicago, Illinois) and were presented by Dr. O. Iqbal at the annual meeting of the American Society of Hematology held in New Orleans this past December. One such anticoagulant, a synthetic pentasaccharide is being developed by Sanofi-Synthelabo as a novel agent with less bleeding potential than standard heparin. In the reported study, reversal of the Sanofi-Synthelabo drug, as measured by anti-Factor Xa activity or the Heptest(TM), was studied in vitro in human plasma. The efficacy of three reversal agents; Neutralase, protamine and platelet factor 4 were compared. Neither protamine nor platelet factor 4 were able to reverse any anticoagulant activity of the pentasaccharide. In contrast, Neutralase was highly effective. In similar studies, Dr. Jawed Fareed and colleagues, as well as IBEX scientists, have demonstrated the ability of Neutralase to reverse the Aventis drug, Lovenox(TM) (enoxaparin), currently the most commonly used low molecular weight heparin with sales for the last three quarters of over US$500 million. "Until now, a specific antidote to neutralize low molecular weight heparins and pentasaccharide is not available. Heparinase I (Neutralase(TM)) may be a useful agent to neutralize the bleeding effects of low molecular weight heparins, their fractions, and chemically synthetic pentasaccharide" concluded Dr. Fareed, Dr. Iqbal and colleagues. IBEX believes this represents a significant commercial opportunity for Neutralase and has initiated collaboration discussions with potential partners. Neutralase(TM) is also being studied in the US and Germany for the reversal of heparin-induced anti-coagulation in coronary artery bypass surgery. IBEX Technologies Inc. is a Canadian biotechnology company developing therapeutic enzymes for heparin reversal, cardiovascular disease and tissue repair. -30- FOR FURTHER INFORMATION PLEASE CONTACT: IBEX Technologies Inc. Paul Baehr Chairman and Chief Executive Officer (514) 344-4004 (514) 344-8827 (FAX) or IBEX Technologies Inc. Robert Heft President and Chief Operating Officer (514) 344-4004 (514) 344-8827 (FAX) Email: Info@IBEX.ca |
|
| aus der Diskussion: | Neues zu IBEX |
| Autor (Datum des Eintrages): | bigcent (09.03.00 18:02:31) |
| Beitrag: | 1 von 4 (ID:595803) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |